Covid inquiry: Failure to consider 'potentially massive impact' of lockdown pre-pandemic
The UK may not have been well prepared “at all”, says the lead lawyer for the Covid inquiry.
Similar Posts
Matt Hancock says UK's pandemic strategy was completely wrong
Planning focused more on burying the dead than averting disaster, ex-health secretary says.
Pentagon waited three days to inform White House that the defense secretary was hospitalized in ICU
WASHINGTON — Amid tensions in the Middle East, Secretary of Defense Lloyd Austin was hospitalized, including spending four days in the intensive care unit, according to two senior administration officials. The Pentagon did not inform senior officials in the White House’s National Security Council of Austin’s hospitalization until Thursday — three days after he arrived…
Respiratory illnesses remain ‘elevated’ throughout much of country: CDC
Join Fox News for access to this content Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the…
Ozempic and Wegovy could lead to muscle loss, experts say, but prevention is possible
Read this article for free! Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the content, check your…
Johnson & Johnson (JNJ) earnings Q4 2023
The stock trading graph of Johnson & Johnson is seen on a smartphone screen. Rafael Henrique | SOPA Images | LightRocket | Getty Images Johnson & Johnson on Tuesday reported fourth-quarter earnings and revenue that narrowly edged out Wall Street’s expectations as sales in the company’s pharmaceutical and medical devices businesses surged. J&J also provided full-year…
Obesity and Alzheimer’s drugs pack one-two punch to lift Eli Lilly
Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three months, as investors book profits in the top performer…